HELPDESK ANSWERSIn patients with hyperlipidemia and cardiovascular disease, does the addition of a PCSK9 inhibitor decrease the incidence of subsequent cardiovascular events?Monroe, Lizzie MD; Evans, Tanner MD; Thacker, Thomas DO, MS; Streicher Green, Vanessa DO Author Information UT Nashville Family Medicine Residency, Murfreesboro, TN The authors declare no conflicts of interest. Evidence-Based Practice 24(10):p 35-36, October 2021. | DOI: 10.1097/EBP.0000000000001239 Buy Metrics Copyright © 2021 by Family Physicians Inquiries Network, Inc.
